tiprankstipranks
Trending News
More News >

CymaBay downgraded to Neutral from Buy at BTIG

BTIG analyst Julian Harrison downgraded CymaBay (CBAY) to Neutral from Buy without a price target following the announcement of its proposed acquisition by Gilead (GILD) for $32.50 per share. The acquisition “makes sense” as the firm sees seladelpar emerging as the preferred PPAR agonist for the treatment of primary biliary cholangitis and is also not aware of any other active PBC programs in Gilead’s pipeline or portfolio of marketed products, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on CBAY:

Disclaimer & DisclosureReport an Issue